Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fotemustine SCHEMBL8880 | 1.00 | ALDH1A1 (0.44) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Fotemustine SCHEMBL16174560 | 1.00 | ALDH1A1 (0.44) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Fotemustine SCHEMBL7206688 | 0.99 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Fotemustine SCHEMBL3982212 | 0.97 | ALDH1A1 (0.42) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Fotemustine SCHEMBL14697056 | 0.90 | ALDH1A1 (0.36) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL25859933 | 0.89 | GAA (0.36) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL17524418 | 0.89 | GAA (0.36) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Fotemustine SCHEMBL4448327 | 0.88 | ADRA2A (0.62) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL10893811 | 0.87 | ALDH1A1 (0.42) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL25860601 | 0.86 | GAA (0.35) | SMN1; SMN2GAACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 51556 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| WO-2025136820-A9 | POLY-ANTIGEN CYTOKINE-RECEPTOR COMPLEXES (PACCS), COMPOSITIONS, AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| CN-1207041-A | Antineoplastic method and compositions employing optically pure (-)-fotemustine | SEPRACOR INC (US) | 1999-02-03 | — | — | CN | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0866712-A4 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE (-)-FOTEMUSTINE | SEPRACOR INC (US) | 1998-12-23 | — | — | EP | claimed |
| EP-0868189-A4 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE | SEPRACOR INC (US) | 1998-12-23 | — | — | EP | claimed |
| EP-0868189-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0866712-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE (-)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1998-09-30 | — | — | EP | claimed |
| WO-1997018818-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1997-05-29 | — | — | WO | claimed |
| WO-1997018819-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE (-)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1997-05-29 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |